British Journal of Cancer - Table of Contents alert Volume 111 Issue 5

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 111, Issue 5 (817-1020) Published online 26 August 2014 In this issue Minireview Clinical Studies Translational Therapeutics Molecular Diagnostics Epidemiology Also new today Advance online publication Digital Edition Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Check out the Top 10 papers from the British Journal of Cancer! British Journal of Cancer presents the top 10 downloaded papers for 2014. Halfway through the year, we've seen some excellent submissions to the journal. Yours could be next.  Click here to find out how you can submit your paper to British Journal of Cancer.   Advertisement This year's EpiC London meeting will show you how to deliver on the promise of epigenetics by enhancing your understanding of the mechanisms of epigenetics regulation and what this means for drug discovery & development. With huge amounts of epigenetic data available, attend this meeting on the 4th-6th November to uncover what that data can really show you.   Minireview Top Oncogenic KRAS signalling in pancreatic cancer S Eser, A Schnieke, G Schneider and D Saur Br J Cancer 2014 111: 817-822; advance online publication, April 22, 2014; 10.1038/bjc.2014.215 Abstract | Full Text Prevalence and implications of elevated microsatellite alterations at selected tetranucleotides in cancer M M C Watson, M Berg and K Søreide Br J Cancer 2014 111: 823-827; advance online publication, April 1, 2014; 10.1038/bjc.2014.167 Abstract | Full Text Clinical Studies Top Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail M Ong, S Carreira, J Goodall, J Mateo, I Figueiredo, D N Rodrigues, G Perkins, G Seed, T A Yap, G Attard and J S de Bono Br J Cancer 2014 111: 828-836; advance online publication, July 1, 2014; 10.1038/bjc.2014.350 Abstract | Full Text The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2− early breast cancer R Exner, Z Bago-Horvath, R Bartsch, M Mittlboeck, V P Retèl, F Fitzal, M Rudas, C Singer, G Pfeiler, M Gnant, R Jakesz and P Dubsky Br J Cancer 2014 111: 837-842; advance online publication, July 8, 2014; 10.1038/bjc.2014.339 Abstract | Full Text Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study C Tian, D J Sargent, T C Krivak, M A Powell, M J Gabrin, S L Brower and R L Coleman Br J Cancer 2014 111: 843-850; advance online publication, July 8, 2014; 10.1038/bjc.2014.375 Abstract | Full Text Management of borderline change in endocervical cells: a more dependable approach S Kodiathodi, S Chattopadhyay, A Baldwin and P Franks Br J Cancer 2014 111: 851-857; advance online publication, June 26, 2014; 10.1038/bjc.2014.340 Abstract | Full Text Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours J Martin-Liberal, M Gil-Martín, M Sáinz-Jaspeado, N Gonzalo, R Rigo, H Colom, C Muñoz, O M Tirado and X García del Muro Br J Cancer 2014 111: 858-865; advance online publication, July 8, 2014; 10.1038/bjc.2014.370 Abstract | Full Text Translational Therapeutics Top Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review J W Boland, K McWilliams, S H Ahmedzai and A G Pockley Br J Cancer 2014 111: 866-873; advance online publication, July 15, 2014; 10.1038/bjc.2014.384 Abstract | Full Text Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells M Valenzuela, C Glorieux, J Stockis, B Sid, J M Sandoval, K B Felipe, M R Kviecinski, J Verrax and P Buc Calderon Br J Cancer 2014 111: 874-882; advance online publication, July 8, 2014; 10.1038/bjc.2014.380 Abstract | Full Text Elevated HOXB9 expression promotes differentiation and predicts a favourable outcome in colon adenocarcinoma patients J Zhan, M Niu, P Wang, X Zhu, S Li, J Song, H He, Y Wang, L Xue, W Fang and H Zhang Br J Cancer 2014 111: 883-893; advance online publication, July 15, 2014; 10.1038/bjc.2014.387 Abstract | Full Text Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours X Zhang, M A Blaskovich, K D Forinash and S M Sebti Br J Cancer 2014 111: 894-902; advance online publication, July 1, 2014; 10.1038/bjc.2014.349 Abstract | Full Text Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle K A Mirza and M J Tisdale Br J Cancer 2014 111: 903-908; advance online publication, August 7, 2014; 10.1038/bjc.2014.379 Abstract | Full Text Molecular Diagnostics Top Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases S A Joosse, V Müller, B Steinbach, K Pantel and H Schwarzenbach Br J Cancer 2014 111: 909-917; advance online publication, July 1, 2014; 10.1038/bjc.2014.360 Abstract | Full Text Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis G Rosin, J de Boniface, G M Karthik, J Frisell, J Bergh and J Hartman Br J Cancer 2014 111: 918-926; advance online publication, July 15, 2014; 10.1038/bjc.2014.398 Abstract | Full Text Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive A O'Toole, A J Michielsen, B Nolan, M Tosetto, K Sheahan, H E Mulcahy, D C Winter, J M Hyland, P R O'Connell, D Fennelly, D O'Donoghue, J O'Sullivan, G A Doherty and E J Ryan Br J Cancer 2014 111: 927-932; advance online publication, July 24, 2014; 10.1038/bjc.2014.367 Abstract | Full Text COUP-TFII regulates metastasis of colorectal adenocarcinoma cells by modulating Snail1 Y Bao, D Gu, W Feng, X Sun, X Wang, X Zhang, Q Shi, G Cui, H Yu, C Tang and A Deng Br J Cancer 2014 111: 933-943; advance online publication, July 17, 2014; 10.1038/bjc.2014.373 Abstract | Full Text Prognostic significance of p62/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma J-L Liu, F-F Chen, J Lung, C-H Lo, F-H Lee, Y-C Lu and C-H Hung Br J Cancer 2014 111: 944-954; advance online publication, July 1, 2014; 10.1038/bjc.2014.355 Abstract | Full Text EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205 P Massoner, T Thomm, B Mack, G Untergasser, A Martowicz, K Bobowski, H Klocker, O Gires and M Puhr Br J Cancer 2014 111: 955-964; advance online publication, July 3, 2014; 10.1038/bjc.2014.366 Abstract | Full Text Epidemiology Top 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence S Vaccarella, S Franceschi, G Engholm, S Lönnberg, S Khan and F Bray Br J Cancer 2014 111: 965-969; advance online publication, July 3, 2014; 10.1038/bjc.2014.362 Abstract | Full Text The psychological impact of participating in colorectal cancer screening by faecal immuno-chemical testing – the Australian experience A Bobridge, P Bampton, S Cole, H Lewis and G Young Br J Cancer 2014 111: 970-975; advance online publication, July 1, 2014; 10.1038/bjc.2014.371 Abstract | Full Text Vitamin D supplements and cancer incidence and mortality: a meta-analysis N Keum and E Giovannucci Br J Cancer 2014 111: 976-980; advance online publication, June 10, 2014; 10.1038/bjc.2014.294 Abstract | Full Text The role of a Mediterranean diet on the risk of oral and pharyngeal cancer M Filomeno, C Bosetti, W Garavello, F Levi, C Galeone, E Negri and C La Vecchia Br J Cancer 2014 111: 981-986; advance online publication, June 17, 2014; 10.1038/bjc.2014.329 Abstract | Full Text Dietary intake of acrylamide and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort M Obón-Santacana, R Kaaks, N Slimani, L Lujan-Barroso, H Freisling, P Ferrari, L Dossus, N Chabbert-Buffet, L Baglietto, R T Fortner, H Boeing, A Tjønneland, A Olsen, K Overvad, V Menéndez, E Molina-Montes, N Larrañaga, M-D Chirlaque, E Ardanaz, K-T Khaw, N Wareham, R C Travis, Y Lu, M A Merritt, A Trichopoulou, V Benetou, D Trichopoulos, C Saieva, S Sieri, R Tumino, C Sacerdote, R Galasso, H B Bueno-de-Mesquita, E Wirfält, U Ericson, A Idahl, N Ohlson, G Skeie, I T Gram, E Weiderpass, N C Onland-Moret, E Riboli and E J Duell Br J Cancer 2014 111: 987-997; advance online publication, June 17, 2014; 10.1038/bjc.2014.328 Abstract | Full Text Childhood brain tumours: associations with parental occupational exposure to solvents S Peters, D C Glass, K R Greenop, B K Armstrong, M Kirby, E Milne and L Fritschi Br J Cancer 2014 111: 998-1003; advance online publication, June 24, 2014; 10.1038/bjc.2014.358 Abstract | Full Text Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy M Kriege, A Hollestelle, A Jager, P E A Huijts, E M Berns, A M Sieuwerts, M E Meijer-van Gelder, J M Collée, P Devilee, M J Hooning, J W M Martens and C Seynaeve Br J Cancer 2014 111: 1004-1013; advance online publication, June 10, 2014; 10.1038/bjc.2014.306 Abstract | Full Text Years of life lost as a measure of cancer burden on a national level O T Brustugun, B Møller and Å Helland Br J Cancer 2014 111: 1014-1020; advance online publication, July 1, 2014; 10.1038/bjc.2014.364 Abstract | Full Text Advertisement British Journal of Cancer has you covered. The British Journal of Cancer publishes significant research that increases the understanding of the causes of cancer; informs about timely detection and accurate diagnosis; helps develop personalised therapy; and drives improvements in the treatment and survival of patients.  Subscribe today and don't miss a beat. Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.